OP
Opthea
OPT.AX·ASXMelbourne AUFounded 200660 employees
Small CapbiotechPublicOphthalmology
Platform: VEGF-C/D
Market Cap
$0.3B
All Drugs
2
Clinical Trials
3
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (OPT.AX)
Loading OPT.AX stock data...
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Pexazanubrutinib | OPT-2935 | Preclinical | 1 | TROP-2 | MDSTTR Amyloidosis | ||
| Zenozumab | OPT-2139 | Phase 3 | 2 | PI3Kα | HCCNASH |
SEC Filings & Financial Documents
SEC filings are not available for ASX-listed companies.
Opthea trades on ASX (AU). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (2)